Labiotech.eu

News and Trends 14 Jul 2023

BioGeneration Ventures closes BGV Fund V at €150M

BioGeneration Ventures (BGV), an early-stage venture capital company in European biopharma, has closed its BGV V fund at €150 million ($167.9 million), its largest fund since launching its first fund in 2006. BGV V was oversubscribed, with demand from both existing and new investors, with existing investors Eli Lilly and Company, Novo Holdings and Bristol […]

July 14, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 14 Jul 2023

Calliditas reveals ‘encouraging results’ from head and neck cancer trial

Calliditas Therapeutics AB has announced interim data from its proof-of-concept phase 2 trial in patients with squamous cell carcinoma of the head and neck (SCCHN) with its lead NOX 1 and 4 inhibitor product candidate, setanaxib. The analysis reflects encouraging early clinical progression-free survival (PFS) results and is supportive of the presumed anti fibrotic mode […]

July 14, 2023 - 3 minutesmins - By Jim Cornall

In Depth 13 Jul 2023

Gold rush over: what happens to biotech now that venture capital is out of reach?

If you were to look back just a little over two years ago to the start of 2021, then putting money into a biotech company seemed like a pretty safe bet. After all, the COVID-19 pandemic had shined a positive spotlight on the biopharmaceutical industry, and initial public offerings (IPOs) were booming. But the last […]

July 13, 2023 - 7 minutesmins - By Willow Shah-Neville

News and Trends 13 Jul 2023

Partnership to progress neurodegenerative disorder treatments

IRBM, Rainwater Charitable Foundation (RCF, Fort Worth, Texas), a private family foundation, and Weill Cornell Medicine (based in New York) are starting a multi-year drug discovery collaboration to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases. The collaboration brings together IRBM’s capabilities in drug discovery and […]

July 13, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 13 Jul 2023

Gene therapy company EG 427 raises €18M

EG 427, a French biotechnology company leading the development of pinpoint DNA medicine solutions, has announced the final closing of a Series A financing. The gene therapy company raised an additional €5 million ($5.6 million) in the final closing from a combination of existing investors and new family office investors, bringing the total raised in […]

July 13, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 12 Jul 2023

New venture capital company Biovance Capital Partners launches

Bionova Capital has started a new venture capital company, Biovance Capital Partners. Bionova Capital is a healthcare-focused investor in early-stage life science companies across Europe. Founded in 2015, Bionova Capital actively manages a portfolio of five companies, two in Portugal, two in the U.K., and one in Spain. The new, independent company is fully owned […]

July 12, 2023 - 3 minutesmins - By Jim Cornall

In Depth 12 Jul 2023

Medicon Valley: how the initiative shaped biotech ecosystems in Denmark and Sweden

With a combined market value of over $7 billion, the life science sectors in Sweden and Denmark are thriving, with over a thousand healthcare companies being set up over the past few years. Much of this is owing to the cross-border cluster that spans regions of eastern Denmark and southern Sweden, the Medicon Valley. Racking […]

July 12, 2023 - 10 minutesmins - By Roohi Mariam Peter

News and Trends 12 Jul 2023

ADC Therapeutics pauses clinical trial following patient deaths

ADC Therapeutics SA has announced a voluntary pause in the enrollment of new patients in the phase 2 LOTIS-9 clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL). The action was taken by ADC Therapeutics after a recent review of aggregate data […]

July 12, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 12 Jul 2023

Pfizer kicks $25M into CellCentric

U.K.-based biotechnology company CellCentric has received a strategic investment from Pfizer including $25 million to help finance further development of inobrodib, its first-in-class p300/CBP inhibitor to treat specific types of cancer. Pfizer will support CellCentric with its own clinical development program in multiple myeloma (MM) for 2024, alongside ongoing trials in specific hematological malignancies, through […]

July 12, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 12 Jul 2023

Crossbow Therapeutics launches with $80M to target cancer

Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, has announced an $80 million Series A funding. The round was led by MPM BioImpact and Pfizer Ventures, with participation from Polaris Partners, BVF Partners, Eli Lilly and Company, Mirae Asset Venture […]

July 12, 2023 - 2 minutesmins - By Jim Cornall

In Depth 11 Jul 2023

AIS Biotech: startup employs carbohydrates to fight the flu

Keen on discovering novel ways to tackle viral infections, AIS Biotech, a French company based in the Alps, aims to combat influenza, more commonly known as the flu, by leveraging the medicinal promise behind glycobiotechnology. A field that has been gaining momentum over the past decade, glycobiotechnology is the study of complex carbohydrates which has […]

July 11, 2023 - 6 minutesmins - By Roohi Mariam Peter

Dr. Grégoire Stik, group leader at the Josep Carreras Leukaemia Research Institute and co-author of the study.

News and Trends 11 Jul 2023

Immune memory research could lead to next generation of epigenetic drugs

A team of researchers has discovered that the memory of the immune system relies on characteristic epigenetic features and a specific 3D arrangement of the DNA in the nucleus of memory cells, allowing for a fast activation of these cells. These features are altered in chronic inflammation diseases like asthma and could be important in […]

July 11, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

BioGeneration Ventures closes BGV Fund V at €150M

Calliditas reveals ‘encouraging results’ from head and neck cancer trial

Gold rush over: what happens to biotech now that venture capital is out of reach?

Partnership to progress neurodegenerative disorder treatments

Gene therapy company EG 427 raises €18M

New venture capital company Biovance Capital Partners launches

Medicon Valley: how the initiative shaped biotech ecosystems in Denmark and Sweden

ADC Therapeutics pauses clinical trial following patient deaths

Pfizer kicks $25M into CellCentric

Crossbow Therapeutics launches with $80M to target cancer

AIS Biotech: startup employs carbohydrates to fight the flu

Immune memory research could lead to next generation of epigenetic drugs

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!